Skip to main content
. 2024 Oct 22;16(21):3558. doi: 10.3390/cancers16213558

Table 5.

Time to next treatment and overall survival rates at 18 months.

18-Month TTNT Rates (N = 200) 18-Month OS
Rates (N = 200)
Total [%] (95% CI) 64.5 (57.3–72.6) 88.1 (82.7–93.8)
Age
  <70 years 65.6 (56.9–75.7) 90.6 (84.8–96.9)
  ≥70 years 62.0 (50.1–76.7) 82.3 (71.5–94.8)
Gender
  Female 63.5 (52.4–77.0) 90.4 (83.2–98.3)
  Male 65.1 (56.1–75.6) 86.5 (79.1–94.5)
BRAF status
  BRAF negative 54.9 (44.0–68.6) 81.0 (70.7–92.9)
  BRAF positive 66.2 (56.2–78.0) 91.4 (85.3–97.8)
AJCC stage (8th edition)
  Stage IIIA 80.7 (62.5–100) 100 (100–100)
  Stage IIIB 72.1 (59.7–87.1) 91.2 (82.1–100)
  Stage IIIC 57.7 (48.3–68.8) 85.5 (78.2–93.4)
  Stage IIID * 83.3 (58.3–100) * 83.3 (58.3–100) *

Time on next treatment (TTNT) and overall survival (OS) at 18 months. N: number of patients included in the analysis, AJCC: American Joint Committee on Cancer; BRAF: BRAF mutation status. * Estimates are uncertain due to the small number of patients (n = 7).